Operating as a separate entity from Cannatrek, the Foundation also aims to increase awareness of the health benefits of medicinal cannabis by promoting research and education to improve community health outcomes. Its support may comprise access to subsidised or free therapies for eligible community members including veterans, first responders, health professionals, the elderly, children, cancer patients, and other vulnerable groups. The Cannatrek Foundation, an independent entity, will continue to distribute and donate medicinal cannabis products provided by the Cannatrek group of companies, to eligible patients.

Currently, Australian patient groups requiring medicinal cannabis treatments are not provided with government support and are not covered by the pharmaceutical benefits scheme if they wish to access cannabis medicines. The Foundation supports these groups by providing them with medicines and healthcare services and intends to engage with the government for expanding future programs.

Cannatrek Group’s Founder and CEO Tommy Huppert says the vision of the Foundation is simple: “We believe in giving back. We aim to make life-changing medicines accessible to all patients in Australia, regardless of their socio-economic status.”

Cannatrek, a leading Australian medicinal cannabis company, has announced today that its hero product, Cannatrek T25® Topaz Flower, is on the cusp of reaching its 500,000th unit sold in Australia.  Since its launch, T25® Topaz has become a trusted prescription product by GPs for their patients.

This milestone is a testament to the continuous quality and reliability of T25® Topaz.

To date, the T25® Topaz flower holds the distinction of being the number #1 most prescribed and consistent medical cannabis product in Australia.

In addition, with the continuous supply of T25® Topaz flower, Cannatrek is pleased to have the ongoing support with its industry partners and remains committed to providing a dependable and uninterrupted supply of this product to those who require it.